Fluoroquinolone antibiotics – EU review advises restrictions for certain infections and warns of rare but serious long lasting adverse reactions

Fluoroquinolones* are a class of broad spectrum antibiotics which include the active substances ciprofloxacin, levofloxacin, ofloxacin and moxifloxacin.

A recent review by the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) of fluoroquinolone antibiotics (used by mouth, injection or inhalation) concluded that these agents have been associated with prolonged (months-years), serious, disabling and potentially irreversible adverse reactions. The review found that these rarely reported long lasting adverse reactions can involve several or multiple organ systems (musculoskeletal, peripheral and central nervous systems). The adverse reactions reported included well established risks such as tendonitis, tendon rupture, neuropsychiatric effects and neuropathies associated with paraesthesia. The review acknowledged however, that fluoroquinolones remain an important treatment option for some bacterial infections.

The PRAC held a public hearing on the topic in June 2018, where patient experiences with these medicines were heard. Patients who had experienced long-lasting serious adverse reactions particularly emphasised the impact on their lives and the importance of judicious use of these agents coupled with high quality information for patients on potential adverse reactions. Having considered the available evidence and patient experiences, the PRAC recommended in October 2018 that fluoroquinolone antibiotic use should be further restricted and the information provided to patients on potential adverse reactions should be expanded to emphasise, in particular, the possibility of persisting effects.

The PRAC review identified data from spontaneous reports and the scientific literature (which primarily consisted of analyses of case reports) on long lasting adverse reactions associated with fluoroquinolone use, and non-clinical mechanistic studies. A review of the EMA’s EudraVigilance database identified 286 cases of serious adverse reactions reported as disabling and lasting 30 days or more without any confounding factors from across the EU over a 21-year period. While cumulative fluoroquinolone patient exposure data is not available for this time period, it is estimated that over 300 million daily doses of fluoroquinolone antibiotics are dispensed yearly*. The primary disorders reported involved the musculoskeletal system and the nervous system, followed by neuropsychiatric disorders and eye disorders (visual impairment). Tendonitis and related reactions were the most commonly reported musculoskeletal effects, while paraesthesia was the most commonly reported nervous system effect.

**Outcome of the review**

- Fluoroquinolones are associated with prolonged serious, disabling and potentially irreversible adverse reactions.
- The use of fluoroquinolones has been restricted, which means that they should not be used:
  1. To treat mild or self-limiting conditions (e.g. pharyngitis, acute bronchitis),
  2. To treat non-bacterial infections,
  3. To prevent traveller’s diarrhoea or to prevent recurring lower urinary tract infections,
  4. To treat mild or moderate bacterial infections unless other antibiotics commonly recommended for these infections are contraindicated.
- For patients with a serious infection (e.g. broncho-pulmonary infections in cystic fibrosis and complicated urinary tract infections) that is susceptible to treatment with these antibiotics, fluoroquinolones remain an important treatment choice.
- Fluoroquinolones should not be used to treat patients who have previously experienced serious adverse reactions while taking a fluoroquinolone.
- Fluoroquinolones should be used with caution in older patients, patients with renal impairment, patients with solid organ transplants and those treated concomitantly with corticosteroids, as the risk of some adverse reactions (tendonitis and tendon rupture) is increased in these patients.
- Patients should be informed of the risks associated with fluoroquinolones prior to initiating treatment.

---

* Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2, Ireland.
T: +353 1 676 4971 E: medsafety@hpra.ie www.hpра.ie
Advice to Healthcare Professionals

- Fluoroquinolones are associated with prolonged (up to months or years), serious, disabling and potentially irreversible adverse reactions affecting several, sometimes multiple, systems, organ classes and senses.
- The adverse reactions include tendonitis, tendon rupture, arthralgia, pain in extremities, gait disturbance, neuropathies associated with paraesthesia, depression, fatigue, memory impairment, sleep disorders and impaired hearing, vision, taste and smell.
- Tendon damage (especially to Achilles tendon but other tendons can also be involved) can occur within 48 hours of commencing treatment or the effects can be delayed for several months after stopping treatment.
- Patients who are older, have renal impairment or have had solid organ transplantation and those being treated with a corticosteroid are at higher risk of tendon damage. Concomitant treatment with a fluoroquinolone and a corticosteroid should be avoided.
- Fluoroquinolones should generally not be used in patients who have had serious adverse reactions associated with the use of quinolone or fluoroquinolone medicines.
- Patients should be advised of the risk of tendon damage and neuropathies and the potential long lasting and serious nature of these effects.
- Patients should be advised to read the package leaflet (PL) that accompanies their medicine.
- Fluoroquinolone treatment should be discontinued and alternative treatment should be considered at the first sign of tendonitis (e.g. painful swelling, inflammation) or symptoms of neuropathy such as pain, burning, tingling, numbness or weakness.
- The PRAC recommendation has now been forwarded by the EMA's Committee for Medicinal Products for Human Use (CHMP) to the European Commission for a legally binding decision.

Key Message

Fluoroquinolones are associated with serious adverse reactions affecting several, sometimes multiple, systems, organ classes and senses which, although rarely reported, may be prolonged, disabling and potentially irreversible.

Fluoroquinolone use has therefore been restricted as detailed above.

Patients who are older, have renal impairment or have had a solid organ transplant and those being treated with a corticosteroid are at higher risk of tendon damage. Concomitant treatment with a fluoroquinolone and a corticosteroid should be avoided.

Patients should be informed of the potentially serious and long lasting adverse reactions associated with fluoroquinolone antibiotics and advised to read the package leaflet that accompanies their medicine.

Patients should be advised to urgently seek medical advice at the first signs of these adverse reactions.

Healthcare professionals should discontinue fluoroquinolone treatment and consider alternative treatment at the first sign of tendonitis, neuropathy or other serious adverse reaction.

Any suspected adverse reactions associated with fluoroquinolone antibiotics should be reported to the HPRA via the usual methods (www.hpra.ie).

Risk of aortic aneurysm and dissection

As highlighted in the 90th edition of the HPRADrug Safety Newsletter, in November 2018, a DHPC was circulated by the MAHs responsible for fluoroquinolones to relevant healthcare professionals regarding a new warning of the rare risk of aortic aneurysm and dissection associated with fluoroquinolones for systemic and inhalation use. In patients at risk of aortic aneurysm and dissection, fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options.
Adverse Reaction Reporting

The HPRA greatly appreciates the contribution to the spontaneous reporting of suspected adverse reactions by busy healthcare professionals. Information collected through this system is an important method of monitoring medicines safety in normal clinical practice, by increasing knowledge about known adverse reactions and also by acting as an early warning system for the identification of previously unrecognised adverse reactions. Such information is one of the tools used by the HPRA and other regulators in the ongoing safety evaluation of marketed medicines.

There are several options in place for reporting suspected adverse reactions to the HPRA, as follows:

- By following the links (‘Report an Issue’ tab) to the online reporting options accessible from the HPRA website homepage (www.hpra.ie);
- Using the downloadable report form also accessible from the HPRA website, which may be completed manually and submitted to the HPRA via ‘freepost’;
- Using the traditional ‘yellow card’ report, which also utilises a freepost system. ‘Yellow cards’ are available from the HPRA Pharmacovigilance department on request.

**Biological Traceability**

EU and national legislation requires clear identification of any biological medicine, which is the subject of a suspected adverse reaction report, indicating that the brand name and batch number of the particular medicinal product should be specified on relevant reports submitted.

**Additional Monitoring**

EU and national legislation also introduced the concept of additional monitoring, to support prompt identification of any new safety hazards associated with particular medicines. Healthcare professionals and patients are particularly encouraged and reminded to report all adverse reactions associated with the use of these medicines, identifiable by an inverted black triangle on the product information. An explanatory statement is included both in the Summary of Product Characteristics (SmPC) and Package Leaflet (PL) for these medicines, together with the symbol:

▶ This medicinal product is subject to additional monitoring.

**Educational Materials**

Educational materials aim to minimise important risks and maximise the risk-benefit balance of a medicinal product. The content of educational materials is intended to supplement the currently authorised product information for the medicinal product concerned in order to support safe and effective prescribing and use. They are designed to fulfil specific risk minimisation objectives and focus on specific safety concern(s) in order to provide clear statements and concise messages describing actions to be taken in order to prevent and minimise these risks. Educational materials are developed by the Marketing Authorisation Holder (MAH) for a medicinal product when specifically recommended by a national competent authority (such as the HPRA) and these must be reviewed and approved by the HPRA prior to distribution to Irish healthcare professionals and patients. Educational materials are available on the HPRA website, accessible via the ‘find a medicine’, ‘advanced search’ option (www.hpra.ie).